BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

Inclusion criteria

• Healthy, adult male or female, 19-50 years of age.
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, or vital signs, as deemed by the Investigator or designee.
• Laboratory results within normal range or not clinically significant as determined by the Investigator at Screening.
• Understands the study procedures in the informed consent form (ICF) and willing and able to comply with the protocol.

Exclusion criteria

• History of any illness, clinically significant medical condition, or disease, that in the opinion of the Investigator or designee might confound the results of the study or pose an additional risk to the subject by participation in the study.
• Major surgery within 4 weeks before study entry or anticipated during the study period.
• Has clinically significant active infectious disease or history of significant infectious disease.
• Participation in another clinical study within 30 days prior to the first dosing or five half-lives of the Investigational Product tested, whichever is longer. The window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
• Female subjects with a positive pregnancy test at the Screening visit or at Check-in, or who are lactating.
• Donation of blood or significant blood loss within 56 days prior to the first dosing.
• Plasma donation within 7 days prior to the first dosing.